| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018459101 |
| P356 | DOI | 10.1007/S00280-014-2648-9 |
| P698 | PubMed publication ID | 25477010 |
| P50 | author | Etsuro Hatano | Q110418582 |
| P2093 | author name string | Daisuke Sakai | |
| Hiroaki Nagano | |||
| Satoshi Morita | |||
| Yutaka Fujiwara | |||
| Tatsuya Ioka | |||
| Shigeru Marubashi | |||
| Atsushi Miyamoto | |||
| Hiroaki Terajima | |||
| Hiroaki Yanagimoto | |||
| Hisanori Shiomi | |||
| Hisashi Ikoma | |||
| Masashi Kanai | |||
| Satoru Seo | |||
| Shinichi Ikuta | |||
| Shogo Kobayashi | |||
| Shoji Kubo | |||
| Tetsuo Ajiki | |||
| Yuzo Kodama | |||
| P2860 | cites work | Biliary tract cancers: current concepts and controversies | Q36066076 |
| Phase II study of S-1 in patients with advanced biliary tract cancer | Q36696249 | ||
| Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. | Q37998654 | ||
| Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy | Q39396983 | ||
| Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). | Q42937632 | ||
| Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). | Q44488107 | ||
| S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial | Q45178446 | ||
| S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study | Q46795508 | ||
| Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. | Q53268257 | ||
| Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography. | Q53421535 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial | Q33365628 | ||
| Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. | Q33385984 | ||
| Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers | Q33386321 | ||
| Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | Q33390747 | ||
| A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer | Q33391729 | ||
| Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. | Q33392786 | ||
| Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601). | Q33403640 | ||
| Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer | Q34063503 | ||
| Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials | Q34576456 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ??? | Q18556397 |
| P304 | page(s) | 293-300 | |
| P577 | publication date | 2014-12-05 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). | |
| P478 | volume | 75 |
| Q98159763 | Genetic analysis in the clinical management of biliary tract cancer |
| Q41389333 | Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case report |
| Q92169020 | Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study |
| Q33428545 | Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer |
| Q93005724 | Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case |
| Q57463236 | Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases |
| Q91758695 | TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study |
| Q92703974 | The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis |
| Q104103065 | The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato-Biliary Oncology Group |
Search more.